Lasmiditan succinate Inhibitor

Name: Lasmiditan succinate Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5759215
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759215

Lasmiditan succinate is a 5-ht (1F) receptor agonist acting on the central nervous system(Ki value of 2.21nM). More details

DISCONTINUED
Click here to view our similar product(s) OR click here to contact our technical support team for suitable replacement.

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Product Name

Lasmiditan succinate, Inhibitor

Full Product Name

Lasmiditan succinate

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

872.81

Solubility

<1mg/ml refers to the product slightly soluble or insoluble

Formula

C42H42F6N6O8

SMILES

OC(=O)CCC(O)=O.CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1.CN1CCC(CC1)C(=O)c1cccc(NC(=O)c2c(F)cc(F)cc2F)n1

CAS Number

439239-92-6

Target & IC50

5-HT(1F): ic50 2.21nM (Ki)

In Vitro

Lasmiditan, a novel serotonin1F receptor agonist, showed specific affinity in vitro for the receptor without any vasoconstrictive action and inhibited markers associated with electrical stimulation of trigeminal ganglion in migraine animal models[1].

Product Categories/Family for Lasmiditan succinate, inhibitor

GPCR/G Protein; 5-HT Receptor; Neuroscience

Product References and Citations for Lasmiditan succinate, inhibitor

Capi M, de Andres, Fernando, Lionetto L, et al. Lasmiditan for the treatment,of migraine[J]. Expert Opinion on Investigational Drugs, 2017, 26(2):227-234.
Capi M, de Andres, Fernando, Lionetto L, et al. Lasmiditan for the treatment,of migraine[J]. Expert Opinion on Investigational Drugs, 2017, 26(2):227-234.
Kuca B, Silberstein S D, Wietecha L, et al. Lasmiditan is an effective acute treatment, for migraine: A phase 3 randomized study[J]. Neurology, 2018, 91(24):10.1212/WNL.0000000000006641.
Kuca B, Silberstein S D, Wietecha L, et al. Lasmiditan is an effective acute treatment, for migraine: A phase 3 randomized study[J]. Neurology, 2018, 91(24):10.1212/WNL.0000000000006641.

Other Notes

Small volumes of Lasmiditan succinate, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Lasmiditan succinate purchase

MBS5759215 is an inhibitor targeting Lasmiditan succinate.